Wealth Enhancement Advisory Services LLC Purchases 1,817 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Wealth Enhancement Advisory Services LLC increased its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 0.9% in the 1st quarter, HoldingsChannel reports. The firm owned 197,493 shares of the company’s stock after acquiring an additional 1,817 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $17,954,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GEHC. Rise Advisors LLC increased its stake in shares of GE HealthCare Technologies by 241.4% in the first quarter. Rise Advisors LLC now owns 338 shares of the company’s stock valued at $31,000 after buying an additional 239 shares during the period. Riverview Trust Co acquired a new position in shares of GE HealthCare Technologies in the first quarter valued at approximately $31,000. Fortitude Family Office LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $29,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $30,000. Finally, Sachetta LLC acquired a new position in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $31,000. Institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on GEHC. Bank of America decreased their target price on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a research report on Wednesday, May 1st. The Goldman Sachs Group initiated coverage on shares of GE HealthCare Technologies in a research report on Thursday, May 30th. They set a “neutral” rating and a $87.00 price objective for the company. Mizuho reduced their price objective on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Citigroup raised their price objective on shares of GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Argus raised their price objective on shares of GE HealthCare Technologies from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $94.09.

Insider Buying and Selling

In other news, CTO Taha Kass-Hout sold 3,300 shares of GE HealthCare Technologies stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $78.70, for a total transaction of $259,710.00. Following the transaction, the chief technology officer now directly owns 67,300 shares of the company’s stock, valued at approximately $5,296,510. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Frank R. Jimenez acquired 1,315 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were acquired at an average cost of $76.52 per share, with a total value of $100,623.80. Following the completion of the acquisition, the insider now owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CTO Taha Kass-Hout sold 3,300 shares of GE HealthCare Technologies stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total value of $259,710.00. Following the completion of the transaction, the chief technology officer now owns 67,300 shares of the company’s stock, valued at $5,296,510. The disclosure for this sale can be found here. Insiders sold 90,482 shares of company stock worth $7,369,137 in the last quarter. 0.27% of the stock is owned by insiders.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $78.81 on Friday. The company has a quick ratio of 0.83, a current ratio of 1.06 and a debt-to-equity ratio of 1.11. The business’s fifty day moving average is $79.98 and its 200 day moving average is $81.68. GE HealthCare Technologies Inc. has a 12-month low of $62.35 and a 12-month high of $94.50. The stock has a market cap of $35.97 billion, a P/E ratio of 23.05, a P/E/G ratio of 2.81 and a beta of 1.22.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.90 earnings per share for the quarter, meeting the consensus estimate of $0.90. The business had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.80 billion. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the business earned $0.85 EPS. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Friday, July 19th will be issued a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.15%. The ex-dividend date of this dividend is Friday, July 19th. GE HealthCare Technologies’s payout ratio is 3.51%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.